Physicians remain vital in obesity care, but they are not the full picture. NPs and PAs are increasingly central to how ...
In today’s Pharmaceutical Executive Daily, we cover Eli Lilly and Novo Nordisk’s plans to bring their leading weight-loss medications to the TrumpRx platform, the State of Texas’ legal move to block ...
The FDA has named six new additions to the Commissioner’s National Priority Voucher (CNPV) program, expanding the initiative to 15 products that address critical public health and national security ...
Johnson & Johnson secures FDA approval for Darzalex Faspro as the first and only treatment for adults with high-risk smoldering multiple myeloma, supported by Phase III Aquila trial data showing a 51% ...
Caplyta is now FDA-approved for MDD treatment in adults, marking its fourth indication, including bipolar I and II depression ...
Recent partnership announcements in the pharma industry reflects the community’s commitment to collaborative innovation, ...
In today’s Pharmaceutical Executive Daily, we cover Kimberly-Clark’s $48.7 billion acquisition of Kenvue, Cencora’s $1 ...
Raj Indupuri, CEO, eClinical Solutions,emphasized that robust data strategy and infrastructure are essential for realizing AI ...
In the third entry of Pharmacuetical Executive’s premium webinar series examining the impact of President Trump’s MFN ...
Novo Nordisk’s amended proposal values Metsera at $86.20-per-share, for a total value upwards of $10 billion, representing an ...
In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s amended proposal to acquire Metsera, the State of Texas’ attempt to block Kenvue’s planned dividend payment, and how data and AI are ...
UCB has announced FDA’s approval of Kygevvi (doxecitine and doxribtimine) for the treatment of adults and pediatric patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback